Safety of anti-thrombotic therapy in acute aortic dissection; single

1

center, observational study 2 3 Kensuke Hori, MD¹; Nagisa Morikawa MD, PhD¹; Eiki Tayama, MD, PhD²; Yoshihiro 4 Fukumoto, MD, PhD1 5 6 7 1) Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume 8 University School of Medicine 9 2) Department of Surgery, Kurume University School of Medicine 10 Short title: Aortic dissection and anti-thrombosis 11 Total word count: 2,514 words of text with 4 figures and 10 tables 12 13 14 Address for correspondence: Yoshihiro Fukumoto MD, PhD 15 Professor and Chairman 16 17 Division of Cardiovascular Medicine, Department of Internal Medicine 18 Kurume University School of Medicine

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19	67 Asahi-machi, Kurume, 830- 0011, Japan
20	(Tel)+81-942-31-7562
21	(Fax)+81-942-33-6509
22	(EM) fukumoto_yoshihiro@med.kurume-u.ac.jp
23	
24	

ABSTRACT

25

26

27

28

29

30

31

32

34

35

36

37

38

39

41

Background

Acute aortic dissection occurs due to a primary tear in aortic intima, with blood from

aortic lumen penetrating into diseased media, in which anti-thrombotic therapies may be

harmful. We examined the prognosis in patients, who had already taken antithrombotic

therapies at the onset of acute aortic dissection, and the safety to administer anti-

thrombotic drugs in acute phase during hospitalization.

Methods and Results

We retrospectively enrolled 685 patients with acute aortic dissection (type A/B: 454/231),

who were transferred to Kurume University Hospital from 2004 to 2020. In both type A

and B, there were no significant differences in in-hospital mortality between with and

without antithrombotic therapies at the onset. Patients, who survived more than a day and

administered anti-thrombotic drugs during hospitalization, had significantly lower in-

hospital mortality than those who had no anti-thrombosis in acute phase in type A, while

there was no significant difference in in-hospital mortality between the 2 groups in type

40 B.

Conclusions

We demonstrated that anti-thrombotic drugs did not worsen the prognosis in patients with

Hori	et	al.	Page	4

43	acute aortic dissection, indicating that we should not hesitate anti-thrombotic drugs if
44	indicated.
45	
46	Key Words: acute aortic dissection; anti-thrombosis; mortality; anti-coagulant; anti-
47	platelet.
48	

Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Acute aortic dissection has poor prognosis, [1, 2] frequently resulting in sudden cardiac death. There are several classifications in acute aortic dissection, in which Stanford type A is classified as "all dissections involving the ascending aorta, regardless of the site of origin", and Stanford type B is as "all dissections not involving the ascending aorta".[3] Historically, the mortality of Stanford type A approaches 1% per hour,[4] and Stanford type B had 10 to 25% of mortality at 30 days.[3] Although diagnostic modalities and therapeutic strategies including surgical and endovascular treatment have recently advanced, mortality rate remains still high.[5] Accumulated evidence has demonstrated that the inflammation plays a central role in the pathogenesis of acute aortic dissection. [6-8] Acute aortic dissection occurs due to a primary tear in a ortic intima, with blood from a ortic lumen penetrating into diseased media.[8] As initial medical therapy, blood pressure, heart rate, and pain should be initially treated to optimize patient stabilization during interhospital transfer and surgical triage.[9] In such situation, data regarding anti-thrombotic therapies remains scant, which seems to be harmful. However, acute aortic dissection suddenly occurs even in patients, who have already taken anti-thrombotic therapies, in the clinical settings. Further, anti-

Hori et al. Page 6

thrombotic drugs are occasionally required for several reasons, such as atrial fibrillation, during the hospitalization of acute aortic dissection.

Currently, it has not been fully elucidated if anti-thrombotic drugs do harm in patients with acute aortic dissection. Therefore, the present study aimed to examine the impact of anti-thrombotic therapies at the onset of acute aortic dissection and the safety of anti-thrombotic agents use during hospitalization in acute phase of acute aortic dissection.

76 **Methods**

Study Design

77

85

86

87

88

89

90

91

92

93

This study was a retrospective observational study using the database of Coronary Care
Unit / Cardiovascular Medicine, Kurume University Hospital. We enrolled patients with
acute aortic dissection, who were transferred to Coronary Care Unit / Cardiovascular
Medicine, Kurume University Hospital from January 2004 to December 2020. The
present study was approved by the institutional review board at Kurume University
(21280). The informed consent was waived due to the retrospective nature and opt-out
was used in the study.

Data Collection

Baseline demographic data, when patients arrive at the hospital, were collected based on the medical records, including age, sex, height, body weight, waist, medications including anti-thrombosis (warfarin, direct oral anti-coagulants (DOAC), aspirin, clopidogrel), traditional risk factors (hypertension, glucose intolerance/diabetes mellitus and dyslipidemia), blood pressure (BP), pulse rate, heart rate, and comorbidities (coronary artery disease, hypertensive heart disease, cardiomyopathy, valvular heart diseases, and congenital heart diseases). Coronary artery diseases included chronic stable angina,

asymptomatic myocardial ischemia, acute coronary syndrome, prior myocardial infarction, prior coronary revascularization, coronary spastic angina, and nonobstructive coronary atherosclerosis. Venous thromboembolism included pulmonary thromboembolism and deep vein thrombosis. Left ventricular (LV) dysfunction was defined as LV ejection fraction <50%. "Genetic and others" includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease. Other clinical diagnosis and medication data were obtained from medical records. All patients were ascertained smoking and drinking habits by a questionnaire. Alcohol intake and smoking were classified as current habitual use or not. Major bleeding was defined as fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, referred to International Society on Thrombosis and Haemostasis.[10] Infarction included myocardial, cerebral, and peripheral, including abdominal and limb, arteries infarction. Data of death during hospitalization were collected based on medical records. All cardiovascular diseases were diagnosed by expert cardiologists.

Blood sampling

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Blood samples were obtained from the antecubital vein and measured at a commercially

available laboratory in Kurume University Hospital. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation modified with a Japanese coefficient[11]: eGFR (ml • min⁻¹ • 1.73 m⁻²) = 194 $\times age^{-0.287} \times serum \quad creatinine^{-1.094} \text{ (if female} \times 0.739).$

Outcome

- Primary outcome was defined as death from any cause during hospitalization, all of
- which were identified in the medical records.

Statistical Analysis

Data were presented mean \pm standard error (SE) and compared between groups using two-sided t-tests. Categorical variables were presented as frequency and percent proportions and compared between groups using chi-square tests. Survival curves of death from all causes were estimated by the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Next, we adjusted the models for age and sex. Statistical significance was defined as p<0.05. All statistical analyses were performed using the SAS system (Release 9.4, SAS Institute, Cary, NC,

130 USA).

132 Results

Transferred patients

133

134

135

136

137

138

139

140

141

A total of 685 patients with acute aortic dissection were transferred to our hospital from January 2004 to December 2020 (**Figure 1**). There were 454 type A and 231 type B patients. In type A, 70 patients were treated by antithrombosis drugs on admission, including 24 with anti-coagulants, 39 anti-platelet drugs, and 7 both (**Figure 1**). Characteristics of transferred patients at baseline were shown in **Table 1**.

Table 1. Clinical characteristics of transferred acute aortic dissection patients

	Stanford type A (n=454)			Stanford type		
Anti-thrombotic therapy	yes	no	P value	yes	no	P value
(at the onset)	(n=70)	(n=384)		(n=38)	(n=193)	
Hospital stay (days)	38.3±35.6	28.9 ± 22.1	0.04	28.7 ± 28.7	26.1 ± 20.5	0.59
Age (years old)	74.8±8.9	68.2 ± 12.2	< 0.01	69.8 ± 15.0	66.0 ± 11.8	0.14
Sex (male)	42 (60.0%)	183 (47.6%)	0.06	21 (55.3%)	137 (71.0%)	0.06
Surgical/endovascular treatment	59 (84.3%)	314 (81.8%)	0.61	3 (7.9%)	30 (15.5%)	0.22
Medical history						
A Fib	22 (31.4%)	13 (3.4%)	< 0.01	9 (23.7%)	2 (1.0%)	< 0.01
CAD	14 (20.0%)	13 (3.4%)	< 0.01	8 (21.1%)	3 (1.6%)	< 0.01
Other CVD	27 (38.6%)	36 (9.7%)	< 0.01	12 (31.6%)	19 (10.0%)	< 0.01
PAD	19 (27.1%)	40 (10.8%)	< 0.01	14 (36.8%)	36 (18.7%)	0.01

VTE	1 (1.4%)	1 (0.3%)	0.18	0 (0.0%)	0 (0.0%)	
НТ	66 (94.3%)	320 (86.5%)	0.07	37 (97.4%)	181 (94.8%)	0.49
DM	7 (10.0%)	26 (7.1%)	0.39	7 (18.9%)	24 (12.6%)	0.3
DLp	18 (25.7%)	78 (21.1%)	0.4	19 (50.0%)	38 (19.9%)	< 0.01
Genetic and others	1 (1.4%)	8 (2.1%)	0.69	4 (10.5%)	4 (2.1%)	< 0.01
Smoking	30 (44.8%)	133 (36.7%)	0.21	20 (54.1%)	127 (67.2%)	0.13
Alcohol	28 (41.8%)	109 (30.2%)	0.06	12 (32.4%)	83 (43.9%)	0.2
Surgical history						
post-AVR	6 (8.6%)	2 (0.5%)	< 0.01	7 (18.4%)	0 (0.0%)	< 0.01
post-MVR	0 (0.0%)	0 (0.0%)		1 (2.6%)	0 (0.0%)	0.02
CABG	2 (2.9%)	1 (0.3%)	0.02	2 (5.3%)	0 (0.0%)	< 0.01
Intervention to aortic						
aneurysm and/or	11 (15.7%)	14 (3.8%)	< 0.01	15 (39.5%)	13 (6.8%)	< 0.01
dissection						
Complication						
Major bleeding	5 (7.1%)	25 (7.0%)	0.96	1 (2.6%)	7 (3.6%)	0.75
Infarctoin by aorite	18 (25.7%)	78 (21.7%)	0.46	0 (0%)	20 (10.4%)	0.04
dissection		/ 0		- / 0		
Paroxymal A Fib	19 (27.1%)	93 (25.9%)	0.83	2 (5.3%)	8 (4.1%)	0.77
Medication on admission						
RAAS inhibitor	31(45.6%)	93 (29.1%)	< 0.01	22 (57.9%)	52 (28.1%)	< 0.01
ССВ	29 (42.7%)	97 (30.3%)	0.05	16 (42.1%)	51 (27.6%)	0.08
β-blocker	26 (38.2%)	31 (9.7%)	< 0.01	12 (31.6%)	29 (15.7%)	0.02
diuretics			0.03		8 (4.3%)	
	9 (13.2%)	18 (5.6%)		2 (5.3%)	` ,	0.8
α-blocker	1 (1.5%)	9 (2.8%)	0.53	0 (0%)	7 (3.8%)	0.22
warfarin	25 (35.7%)	0 (0.0%)		13 (34.2%)	0 (0.0%)	
DOAC	6 (8.6%)	0 (0.0%)		3 (7.9%)	0 (0.0%)	
aspirin	27 (38.6%)	0 (0.0%)		20 (52.6%)	0 (0.0%)	
clopidogrel	12 (17.1%)	0 (0.0%)		5 (13.2%)	0 (0.0%)	
cilostazol	8 (11.4%)	0 (0.0%)		4 (10.5%)	0 (0.0%)	

prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	
Discharge medicine						
RAAS inhibitor	34 (57.6%)	199 (64.0%)	0.35	23 (62.2%)	149 (84.7%)	< 0.01
CCB	26 (44.1%)	162 (52.1%)	0.26	28 (75.7%)	163 (92.6%)	< 0.01
β-blocker	46 (78.0%)	248 (79.7%)	0.76	33 (89.2%)	158 (89.8%)	0.92
diuretics	21 (35.6%)	103 (33.1%)	0.71	8 (21.6%)	47 (26.7%)	0.91
α-blocker	2 (3.4%)	11 (3.5%)	0.96	2 (5.4%)	14 (8.0%)	0.59
warfarin	17 (28.3%)	59 (18.9%)	0.09	8 (21.6%)	2 (1.1%)	< 0.01
DOAC	6 (10.0%)	15 (4.8%)	0.11	3 (8.1%)	2 (1.1%)	0.01
aspirin	24 (40.0%)	76 (24.3%)	0.01	12 (32.4%)	8 (4.5%)	< 0.01
clopidogrel	5 (8.3%)	6 (1.9%)	< 0.01	5 (13.5%)	0 (0.0%)	< 0.01
cilostazol	5 (8.3%)	1 (0.3%)	< 0.01	1 (2.7%)	0 (0.0%)	0.03
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	

Data are mean \pm SE, or mean (%), BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

142

143

144

145

146

147

148

In type A, patients, who were already treated by anti-thrombosis, had significantly older age, higher prevalence of previous history of atrial fibrillation, cardiovascular diseases, coronary artery bypass graft, and aortic valve replacement, and renin-angiotensin-aldosterone system (RAAS) inhibitors (angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers), calcium channel blocker, and β -blocker use. Among them, 10 patients (14.3%) died during the hospitalization (**Figure 1**).

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

Figure 1. Enrollment of transferred patients with acute aortic dissection Among 685 transferred patients, 15% in 454 type A and 16% in 231 type B patients had already taken anti-thrombotic drugs. In the remaining 384 patients with type A, who have not treated by antithrombosis drugs, 63 patients (16.4%) died during the hospitalization (Figure 1). In Kaplan-Meier curve, patients treated by antithrombosis drugs on admission did not show worse prognosis compared with no anti-thrombosis drug group in type A (Figure 2A). Figure 2. Kapan-Meier curves of transferred patients with acute aortic dissection There were no significant differences in survival rate between with and without antithrombotic drugs on admission in both type A (panel A) and B (panel B). In type B, 38 patients were treated by antithrombosis drugs on admission, including 11 with anti-coagulants, 22 anti-platelet drugs, and 5 both, who had significantly higher prevalence of previous history of atrial fibrillation, coronary artery disease, dyslipidemia, aortic valve replacement, and coronary artery bypass graft, and

RAAS inhibitors use (**Figure 1**, **Table 1**). Among them, 1 patient (2.6%) died during the hospitalization. In the remaining 193 patients with type B, who have not treated by anti-thrombosis drugs, 14 patients (7.3%) died during the hospitalization. Kaplan-Meier curve indicated the comparable prognosis between the 2 groups of type B (**Figure 2B**).

Hospitalized patients

A total of 650 patients with acute aortic dissection survived for more than a day and hospitalized (**Figure 3**). There were 424 type A and 226 type B patients. In type A, 182 patients were treated by antithrombosis drugs during hospitalization, including 64 with anti-coagulants, 73 anti-platelet drugs, and 45 both. Characteristics of hospitalized patients at baseline were shown in **Table 2**. Type A patients had significantly higher prevalence of atrial fibrillation and genetic and other aortic diseases, including Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease (**Table 2**).

Table 2. Clinical characteristics of hospitalized acute aortic dissection

Stanford type A (n=424)			Stanford type			
Anti-thrombotic			_			
therapy	yes	no	P	yes	no	P value
(at the onset)	(n=182)	(n=242)	value	(n=42)	(n=184)	
Hospital stay (days)	36.9±24.5	29.1 ± 23.8	< 0.01	35.6±30.8	25.7 ±20.0	0.01

Age (years old)	69.9±11.3	68.3 ± 12.3	0.17	67.8±15.0	66.4 ± 11.8	0.51
Sex (male)	91 (50.0%)	120 (49.6%)	0.9	23 (54.8%)	131 (71.2%)	0.04
Surgical/endovascular treatment	177 (97.3%)	194 (80.2%)	<0.01	6 (14.3)	25 (13.6)	0.91
Medical history						
A Fib	25 (13.7%)	9 (3.7%)	< 0.01	6 (14.3%)	4 (2.2%)	< 0.01
CAD	13 (7.1%)	11 (4.6%)	0.27	7 (16.7%)	4 (2.2%)	< 0.01
Other CVD	34 (18.7%)	27 (11.3%)	0.03	9 (21.4%)	20 (10.9%)	0.06
PAD	23 (12.6%)	32 (13.5%)	0.81	12 (28.6%)	37 (20.1%)	0.49
VTE	2 (1.1%)	0 (0.0%)	0.11	0 (0.0%)	0 (0.0%)	
НТ	159 (87.4%)	213 (90.3%)	0.35	40 (95.2%)	175 (95.1%)	0.97
DM	17 (9.3%)	15 (6.4%)	0.26	7 (17.1%)	23 (12.5%)	0.44
DLp	37 (20.3%)	55 (23.4%)	0.45	16 (38.1%)	39 (21.2%)	0.02
Genetic and others	7 (3.8%)	1 (0.4%)	0.01	4 (9.5%)	4 (2.2%)	0.02
Smoking	65 (35.7%)	95 (41.1%)	0.26	23 (56.1%)	122 (67.0%)	0.18
Alcohol	60 (33.0%)	75 (32.6%)	0.94	13 (31.7%)	81 (44.5%)	0.13
Surgical history						
post-AVR	5 (2.7%)	2 (0.8%)	0.13	6 (14.3%)	1 (0.5%)	< 0.01
post-MVR	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.5%)	0.63
CABG	2 (1.1%)	1 (0.4%)	0.42	2 (4.8%)	0 (0.0%)	< 0.01
Intervention to aortic						
aneurysm and/or	13 (7.1%)	10 (4.2%)	0.2	10 (24.4%)	17 (9.2%)	< 0.01
dissection						
Complication						
Major bleeding	8 (4.5%)	18 (7.8%)	0.17	0 (0%)	6 (3.3%)	0.24
Infarctoin by aoritc dissection	45 (25.1%)	41 (17.8%)	0.07	4 (9.5%)	16 (8.7%)	0.86
Paroxymal A Fib	77 (43.0%)	35 (15.2%)	< 0.01	3 (7.1%)	7 (3.8%)	0.34
Medication on						
admission						
RAAS inhibitor	58 (35.4%)	61 (29.3%)	0.22	18 (42.9%)	56 (31.3%)	0.15

Hori et al. Page 17

ССВ	55 (33.5%)	66 (31.7%)	0.71	12 (28.6%)	54 (30.2%)	0.84
β-blocker	30 (18.3%)	24 (11.5%)	0.07	8 (19.0%)	32 (17.9%)	0.86
diuretics	15 (9.2%)	10 (4.8%)	0.09	1 (2.4%)	7 (3.9%)	0.63
α-blocker	2 (1.2%)	7 (3.4%)	0.18	0 (0%)	7 (3.9%)	0.19
warfarin	20 (12.1%)	4 (1.9%)	< 0.01	10(23.8%)	2 (1.1%)	< 0.01
DOAC	5 (3.0%)	1 (0.5%)	0.05	3 (7.1%)	0 (0.0%)	< 0.01
aspirin	15 (9.0%)	9 (4.3%)	0.06	15 (35.7%)	5 (2.8%)	< 0.01
clopidogrel	9 (5.4%)	3 (1.4%)	0.03	5 (11.9%)	0 (0%)	< 0.01
cilostazol	4 (2.4%)	4 (1.9%)	0.74	3 (7.1%)	1 (0.5%)	< 0.01
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	
Discharge medicine						
RAAS inhibitor	107 (61.5%)	126 (64.3%)	0.58	28 (68.3%)	144 (83.7%)	0.02
ССВ	75 (43.1%)	113 (57.7%)	< 0.01	31 (75.6%)	160 (93.0%)	< 0.01
β-blocker	146 (83.9%)	148 (75.5%)	0.046	35 (85.4%)	156 (90.7%)	0.31
diuretics	54 (31.0%)	70 (35.7%)	0.34	11 (26.8%)	44 (25.6%)	0.87
α-blocker	5 (2.9%)	8 (4.1%)	0.53	3 (7.3%)	13 (7.6%)	0.96
warfarin	76 (42.7%)	0 (0.0%)	< 0.01	10 (24.4%)	0 (0.0%)	< 0.01
DOAC	21 (11.8%)	0 (0.0%)	< 0.01	5 (12.2%)	0 (0.0%)	< 0.01
aspirin	100 (56.2%)	0 (0.0%)	< 0.01	20 (48.8%)	0 (0.0%)	< 0.01
clopidogrel	11 (6.2%)	0 (0.0%)	< 0.01	5 (12.2%)	0 (0.0%)	< 0.01
cilostazol	6 (3.4%)	0 (0.0%)	< 0.01	1 (2.4%)	0 (0.0%)	0.04
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	

Data are mean ± SE, or mean (%), BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosteron system, CCB; calcium channel blocker, DOAC; direct oral anticoagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Among them, 4 patients (2.2%) died during hospitalization, and 178 (97.8%) were discharged (Figure 3). In the remaining 242 patients with type A, who have not been treated by anti-thrombosis drugs, 39 patients (16.1%) died and 203 (83.9%) were discharged (Figure 3). Kaplan-Meier curve showed the significantly better prognosis in patients treated by antithrombosis drugs in type A (Figure 4A). Figure 3. Enrollment of hospitalized patients with acute aortic dissection Among 650 hospitalized patients, 43% in 424 type A and 19% in 225 type B patients were treated by anti-thrombotic drugs during hospitalization. Figure 4. Kapan-Meier curves of hospitalized patients with acute aortic dissection Survival rate was significantly better in anti-thrombotic drug group than the other in type A (panel A), while there was no significant difference between with and without antithrombotic drugs during hospitalization in type B (panel B). In 226 type B patients, 42 patients were treated by antithrombosis drugs, including 15 with anti-coagulants, 26 anti-platelet drugs, and 1 both (Figure 3), who had significantly higher prevalence of atrial fibrillation, coronary artery diseases, aortic valve

replacement, and coronary artery bypass graft (**Table 2**). Among them, 1 patient (2.4%) died, and 41 were discharged. In the remaining 184 type B patients, who have not treated by anti-thrombosis drugs, 9 patients (4.9%) died during hospitalization (**Figure 3**). In Kaplan-Meier curve, there were no significant difference in prognosis in type B (**Figure 4B**).

Cox proportional hazards regression analysis of all-cause death in TRANSFERRED

patients in type A

In the Cox proportional hazards regression analysis of all-cause death, systolic blood pressure, eGFR, history of hypertension, smoking habit, alcohol intake, complication of surgical procedures, and use of α -blocker were significantly associated with all-cause death (**Table 3**). In this analysis, the use of anti-thrombosis (warfarin, DOAC, aspirin, clopidogrel) was not the predictor of all cause death (**Table 3**).

Table 3. Cox proportional hazard model in transferred acute aortic dissection patients (type A)

	β	SE	p-value
Age	0.01	0.01	0.23
Sex	-0.02	0.23	0.94
Systolic BP	-0.02	< 0.01	< 0.01

Diastolic BP	-0.01	0.008	0.19
Heart rate	0.011	0.006	0.05
eGFR	-0.028	0.006	< 0.01
Past history			
A Fib	-1.05	0.72	0.15
CAD	0.76	0.4	0.06
Other CVD	0.005	0.36	0.99
PAD	0.16	0.35	0.64
VTE	-12.01	744.56	0.99
LV dysfunction	-13.03	789.73	0.99
HT	-0.8	0.31	0.01
DM	-0.55	0.59	0.35
DLp	-0.23	0.33	0.49
Genetic and others	0.57	0.62	0.35
Smoking	-0.64	0.31	0.04
Alcohol	-0.68	0.34	0.04
post-AVR	1.02	0.59	0.09
post-MVR	0		
CABG	-12.01	627.8	0.98
Intervention to aortic	0.27	0.47	0.57
aneurysm and/or dissection			
Complication			
Major bleeding	1.52	0.32	< 0.01
Infarction by aortic dissection	1.54	0.27	< 0.01
Paroxymal A Fib	-1.66	0.52	< 0.01
Medication on admission			
RAAS inhibitor	-0.06	0.31	0.85
CCB	0.36	0.29	0.22
β-blocker	0.04	0.39	0.93
diuretics	0.6	0.44	0.17
α-blocker	1.2	0.52	0.02
warfarin	0.16	0.53	0.77

DOAC	-13.03	787.37	0.99
aspirin	0.8	0.41	0.05
clopidogrel	-14.17	771.42	0.99
cilostazol	-13.03	673.45	0.98
prasugrel	0		
other anti-platelet drug	1.18	1.01	0.24
Anti-coagulant (warfarin or	-0.33	0.52	0.52
DOAC)			
Anti-platelet drug (aspirin,	-0.02	0.38	0.96
clopidogrel, cilostazol, or			
prasugrel)			
Both anti-coagulant and anti-	0.55	0.72	0.44
platelet			
Anti-coagulant or anti-platelet	-0.26	0.34	0.45

SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosteron system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

217

218

219

220

221

222

After adjustment for age and sex, systolic blood pressure, eGFR, history of hypertension, smoking habit, alcohol intake, complication of surgical procedures, and use of α -blocker were significantly associated with all-cause death (**Table 4**). Also, the use of anti-thrombosis (warfarin, DOAC, aspirin, clopidogrel) was not the predictor of all cause death (**Table 4**).

Table 4. Age and sex-adjusted Cox proportional hazard model in transferred acute aortic dissection patients (type A)

224

	β	SE	p-value
C 4 I' DD			
Systolic BP	-0.02	0.004	< 0.01
Diastolic BP	-0.01	0.008	0.17
Heart rate	0.01	0.006	0.07
eGFR	-0.03	0.006	< 0.01
Past history			
A Fib	-1.21	0.72	0.10
CAD	0.7	0.4	0.09
Other CVD	-0.08	0.37	0.83
PAD	0.05	0.36	0.89
VTE	-12.06	752.05	0.99
LV dysfunction	-12.99	788.9	0.99
HT	-0.88	0.32	< 0.01
DM	-0.58	0.59	0.33
DLp	-0.2	0.34	0.56
Genetic and others	0.71	0.63	0.26
Smoking	-0.86	0.36	0.02
Alcohol	-0.8	0.38	0.03
post-AVR	1.01	0.61	0.10
post-MVR	0 .	,	
CABG	-12.24	633.99	0.98
Intervention to aortic	0.18	0.49	0.72
aneurysm and/or dissection			
Complication			
Major bleeding	1.48	0.32	< 0.01
Infarction by aortic dissection	1.52	0.27	< 0.01
Paroxymal A Fib	-1.75	0.52	< 0.01

Medication on admission			
RAAS inhibitor	-0.14	0.31	0.66
CCB	0.29	0.29	0.33
β-blocker	-0.05	0.39	0.89
diuretics	0.48	0.44	0.27
α-blocker	1.16	0.52	0.03
warfarin	-0.002	0.54	0.99
DOAC	-13.24	796.32	0.99
aspirin	0.75	0.42	0.07
clopidogrel	-14.35	776.75	0.99
cilostazol	-13.12	675.96	0.98
prasugrel	0		
other anti-platelet drug	1.14	1.02	0.27
Anti-coagulant (warfarin or	-0.48	0.53	0.36
DOAC)			
Anti-platelet drug (aspirin,	-0.11	0.38	0.78
clopidogrel, cilostazol, or			
prasugrel)			
Both anti-coagulant and anti-	0.49	0.72	0.50
platelet			
Anti-coagulant or anti-platelet	-0.41	0.36	0.25

Cox proportional hazards regression analysis of all-cause death in TRANSFERRED

patients in type B

226

227

228

229

230

231

232

In the Cox proportional hazards regression analysis of all-cause death, systolic blood pressure, heart rate, eGFR, the history of atrial fibrillation, complication of surgical procedures, and use of diuretics were significantly associated with all-cause death (**Table** 5). Also in this analysis, the use of anti-thrombosis (warfarin, DOAC, aspirin,

clopidogrel) was not the predictor of all cause death (Table 5).

Table 5. Cox proportional hazard model in transferred acute aortic dissection

patients (type B)

233

234

235

	β	SE	p-value
Age	0.0005	0.02	0.98
Sex	-0.64	0.65	0.32
Systolic BP	-0.03	0.01	0.02
Diastolic BP	-0.02	0.02	0.24
Heart rate	0.03	0.01	0.04
eGFR	-0.02	0.01	0.04
Past history			
A Fib	1.93	0.67	< 0.01
CAD	-14.08	1484	0.99
Other CVD	0.18	0.77	0.81
PAD	0.47	0.6	0.43
VTE	0 .		
LV dysfunction	0 .		
HT	14.09	1400	0.99
DM	0.12	0.77	0.87
DLp	-0.04	0.66	0.95
Genetic and others	-14.07	1509	0.99
Smoking	0.21	0.6	0.72
Alcohol	-0.2	0.57	0.73
post-AVR	-14.09	1577	0.99
post-MVR	-11.01	1501	0.99
CABG	-12.01	1543	0.99
Intervention to aortic	-0.45	1.04	0.67
aneurysm and/or dissection			

Complication			
Major bleeding	3.87	0.59	< 0.01
Infarction by aortic dissection	2.04	0.57	< 0.01
Paroxymal A Fib	-14.09	1435	0.99
Medication on admission			
RAAS inhibitor	-16.67	1711	0.99
CCB	0.14	0.61	0.82
β-blocker	-0.2	0.78	0.80
diuretics	1.9	0.79	0.02
α-blocker	-14.05	1838	0.99
warfarin	0.4	1.06	0.71
DOAC	-13.02	2047	0.99
aspirin	-15.16	1903	0.99
clopidogrel	-13.04	2043	0.99
cilostazol	-13.05	1571	0.99
prasugrel	0		
other anti-platelet drug	-12.01	2086	0.99
Anti-coagulant (warfarin or	-0.12	1.04	0.91
DOAC)			
Anti-platelet drug (aspirin,	-15.19	1457	0.99
clopidogrel, cilostazol, or			
prasugrel)			
Both anti-coagulant and anti-	-13.03	1218	0.99
platelet	1.00	1.04	0.22
Anti-coagulant or anti-platelet	-1.02	1.04	0.33

After adjustment for age and sex, systolic blood pressure, heart rate, eGFR, the history of atrial fibrillation, complication of surgical procedures, and use of diuretics were significantly associated with all-cause death (**Table 6**), and the use of anti-thrombosis was not the predictor of all cause death (**Table 6**).

Table 6. Age and sex-adjusted Cox proportional hazard model in transferred acute aortic dissection patients (type B)

243

	β	SE	p-value
Systolic BP	-0.03	0.01	0.01
Diastolic BP	-0.02	0.02	0.18
Heart rate	0.03	0.02	0.05
eGFR	-0.02	0.01	0.02
Past history			
A Fib	2.05	0.69	< 0.01
CAD	-14	1480	0.99
Other CVD	0.16	0.78	0.83
PAD	0.5	0.61	0.41
VTE	0		
LV dysfunction	0		
HT	14.07	1400	0.99
DM	0.17	0.77	0.82
DLp	-0.02	0.66	0.98
Genetic and others	-14.11	1513	0.99
Smoking	-0.01	0.7	0.99
Alcohol	-0.39	0.6	0.52
post-AVR	-14.02	1587	0.99
post-MVR	-11.13	1515	0.99
CABG	-12.16	1558	0.99
Intervention to aortic	-0.41	1.05	0.70
aneurysm and/or dissection			
Complication			
Major bleeding	4.24	0.71	< 0.01
Infarction by aortic dissection	2.04	0.57	< 0.01
Paroxymal A Fib	-13.95	1435	0.99

Medication on admission			
RAAS inhibitor	-16.6	1710	0.99
CCB	0.33	0.63	0.60
β-blocker	-0.05	0.78	0.94
diuretics	1.83	0.79	0.02
α-blocker	-13.97	1835	0.99
warfarin	0.7	1.07	0.51
DOAC	-13.25	2020	0.99
aspirin	-15.33	1875	0.99
clopidogrel	-13.26	2052	0.99
cilostazol	-13.68	1616	0.99
prasugrel	0		
other anti-platelet drug	-12.41	2152	0.99
Anti-coagulant (warfarin or	0.05	1.05	0.96
DOAC)			
Anti-platelet drug (aspirin,	-15.19	1449	0.99
clopidogrel, cilostazol, or			
prasugrel)			
Both anti-coagulant and anti-	-13.01	1217	0.99
platelet			
Anti-coagulant or anti-platelet	-0.94	1.05	0.37

Cox proportional hazards regression analysis of all-cause death in HOSPITALIZED

patients in type A

245

246

247

248

249

250

251

In the analysis of all-cause death, systolic blood pressure, eGFR, complication of surgical procedures, and use of α -blocker and anti-thrombosis drugs were significantly associated with all-cause death (**Table 7**). The use of anti-thrombosis (warfarin, DOAC, aspirin, clopidogrel) significantly reduced hazard ratio (**Table 7**).

Table 7. Cox proportional hazard model in hospitalized acute aortic dissection patients (type A)

253

	β	SE	p-value
Age	0.006	0.01	0.65
Sex	-0.11	0.31	0.72
Systolic BP	-0.02	0.006	< 0.01
Diastolic BP	-0.005	0.01	0.63
Heart rate	0.01	0.008	0.11
eGFR	-0.028	0.007	< 0.01
Past history			
A Fib	-1.34	1.01	0.19
CAD	0.67	0.53	0.21
Other CVD	0.22	0.42	0.60
PAD	0.04	0.45	0.93
VTE	-12.01	915.23	0.99
LV dysfunction	-13.04	930.19	0.99
HT	-0.28	0.48	0.56
DM	-0.56	0.73	0.44
DLp	-0.23	0.42	0.58
Genetic and others	0.47	0.77	0.54
Smoking	-0.52	0.36	0.15
Alcohol	-0.52	0.38	0.18
post-AVR	1.03	0.73	0.16
post-MVR	0 .		
CABG	-12.01	776.4	0.99
Intervention to aortic	0.1	0.61	0.87
aneurysm and/or dissection			
Complication			
Major bleeding	1.66	0.38	< 0.01

Infarction by aortic dissection	1.63	0.33	< 0.01
Paroxymal A Fib	-1.27	0.53	0.02
Medication on admission			
RAAS inhibitor	-0.073	0.38	0.85
CCB	0.54	0.35	0.12
β-blocker	-0.1	0.49	0.84
diuretics	0.58	0.54	0.28
α-blocker	1.32	0.61	0.03
warfarin	0.23	0.61	0.71
DOAC	-13.03	969.9	0.99
aspirin	0.61	0.54	0.26
clopidogrel	-14.21	884.34	0.99
cilostazol	-13.04	823.72	0.99
prasugrel	0		
other anti-platelet drug	1.69	1.02	0.10
Anti-thrombus during			
hospitalization			
Anti-coagulant (warfarin or	-1.62	0.6	< 0.01
DOAC)			
Anti-platelet drug (aspirin,	-2.88	1.01	< 0.01
clopidogrel, cilostazol, or			
prasugrel)	15.0	060.56	0.00
Both anti-coagulant and anti-	-15.2	860.56	0.99
platelet	-2.12	0.53	< 0.01
Anti-coagulant or anti-platelet	-2.12	0.33	\0.01

After adjustment for age and sex, systolic blood pressure, eGFR, complication of surgical procedures, and use of α -blocker were significantly associated with all-cause death (**Table 8**). Also in this analysis, the use of anti-thrombosis was also the significant and strong predictor of reduced all cause death (**Table 8**).

Table 8. Age and sex-adjusted Cox proportional hazard model in hospitalized acute aortic dissection patients (type A)

261

- ,			
	β	SE	p-value
Systolic BP	-0.02	0.006	< 0.01
Diastolic BP	-0.005	0.01	0.61
Heart rate	0.012	0.008	0.12
eGFR	-0.028	0.007	< 0.01
Past history			
A Fib	-1.48	1.02	0.15
CAD	0.63	0.53	0.23
Other CVD	0.17	0.42	0.69
PAD	-0.04	0.46	0.93
VTE	-12.04	919.33	0.99
LV dysfunction	-13.02	930.55	0.99
HT	-0.33	0.48	0.50
DM	-0.58	0.73	0.42
DLp	-0.2	0.42	0.63
Genetic and others	0.58	0.78	0.46
Smoking	-0.78	0.42	0.06
Alcohol	-0.65	0.43	0.13
post-AVR	1.004	0.75	0.18
post-MVR	0 .		
CABG	-12.14	778.45	0.99
Intervention to aortic	0.019	0.63	0.98
aneurysm and/or dissection			
Complication			
Major bleeding	1.62	0.39	< 0.01
Infarction by aortic dissection	1.64	0.33	< 0.01
Paroxymal A Fib	-1.34	0.53	0.01

Medication on admission			
RAAS inhibitor	-0.11	0.38	0.77
CCB	0.52	0.36	0.14
β-blocker	-0.15	0.49	0.76
diuretics	0.52	0.54	0.34
α-blocker	1.31	0.61	0.03
warfarin	0.14	0.63	0.83
DOAC	-13.12	972.53	0.99
aspirin	0.55	0.55	0.31
clopidogrel	-14.39	881.58	0.99
cilostazol	-13.05	824.28	0.99
prasugrel	0	•	
other anti-platelet drug	1.62	1.03	0.12
Anti-thrombus during			
hospitalization			
Anti-coagulant (warfarin or	-1.64	0.6	< 0.01
DOAC)			
Anti-platelet drug (aspirin,	-2.9	1.01	< 0.01
clopidogrel, cilostazol, or			
prasugrel)			
Both anti-coagulant and anti-	-15.19	859.87	0.99
platelet	. . –	0	0.01
Anti-coagulant or anti-platelet	-2.17	0.53	<0.01

Cox proportional hazards regression analysis of all-cause death in HOSPITALIZED

patients in type B

263

264

265

266

267

268

In the analysis of all-cause death, heart rate, history of atrial fibrillation and complication of surgical procedures were significantly associated with all-cause death (**Table 9**). In this analysis, the use of anti-thrombosis was not the predictor of all cause death predictor

of all cause death (Table 9).

Table 9. Cox proportional hazard model in hospitalized acute aortic dissection

patients (type B)

269

270

271

	β	SE	p-value
Age	0.004	0.025	0.88
Sex	-0.65	0.79	0.41
Systolic BP	-0.011	0.014	0.40
Diastolic BP	-0.002	0.018	0.90
Heart rate	0.033	0.016	0.04
eGFR	-0.022	0.012	0.08
Past history			
A Fib	1.79	0.8	0.03
CAD	-14.08	1721	0.99
Other CVD	-15.23	1650	0.99
PAD	0.44	0.69	0.53
VTE	0 .		
LV dysfunction	0 .		
HT	14.1	1594	0.99
DM	-0.38	1.06	0.72
DLp	-1.02	1.05	0.33
Genetic and others	-14.07	1681	0.99
Smoking	0.26	0.69	0.71
Alcohol	-0.15	0.65	0.82
post-AVR	-14.1	1749	0.99
post-MVR	-11.01	2104	0.99
CABG	-12.01	1962	0.99
Intervention to aortic	-15.21	1776	0.99
aneurysm and/or dissection			

Complication			
Major bleeding	3.82	0.68	< 0.01
Infarction by aortic dissection	2.58	0.66	< 0.01
Paroxymal A Fib	-14.1	1623	0.99
Medication on admission			
RAAS inhibitor	-16.67	1876	0.99
CCB	-0.014	0.69	0.98
β-blocker	-0.81	1.06	0.44
diuretics	-14.05	2135	0.99
α-blocker	-14.05	2021	0.99
warfarin	-15.13	2435	0.99
DOAC	-13.02	2372	0.99
aspirin	-15.17	2114	0.99
clopidogrel	-12.03	1628	0.99
cilostazol	-13.06	1757	0.99
prasugrel	0		
other anti-platelet drug	-12.01	2395	0.99
Anti-thrombus during			
hospitalization			
Anti-coagulant (warfarin or	-15.13	2087	0.99
DOAC)			
Anti-platelet drug (aspirin,	-0.38	1.06	0.72
clopidogrel, cilostazol, or			
prasugrel) Both anti-coagulant and anti-	-12.01	1770	0.99
platelet	-12.01	1//0	0.77
Anti-coagulant or anti-platelet	-0.91	1.06	0.39

After adjustment for age and sex, history of atrial fibrillation and complication of surgical procedures were significantly associated with all-cause death (**Table 10**). Also, the use of anti-thrombosis was not the predictor of all cause death predictor of all cause

273

274

275

death (Table 10).

277

278

279

280

Table 10. Age and sex-adjusted Cox proportional hazard model in hospitalized acute

aortic dissection patients (type B)

	β	SE	p-value
Systolic BP	-0.012	0.014	0.37
Diastolic BP	-0.005	0.019	0.79
Heart rate	0.035	0.018	0.05
eGFR	-0.025	0.013	0.05
Past history			
A Fib	1.87	0.83	0.02
CAD	-13.99	1722	0.99
Other CVD	-15.32	1649	0.99
PAD	0.44	0.71	0.53
VTE	0 .		
LV dysfunction	0 .		
HT	14.09	1589	0.99
DM	-0.32	1.06	0.76
DLp	-1	1.06	0.34
Genetic and others	-13.84	1682	0.99
Smoking	-0.099	0.8	0.90
Alcohol	-0.42	0.68	0.54
post-AVR	-13.79	1754	0.99
post-MVR	-11.24	2140	0.99
CABG	-12.21	1995	0.99
Intervention to aortic	-15.16	1769	0.99
aneurysm and/or dissection			
Complication			
Major bleeding	4.17	0.81	< 0.01

2.6	0.66	< 0.01
-13.95	1622	0.99
-16.64	1879	0.99
0.14	0.71	0.85
-0.7	1.02	0.51
-14.13	2151	0.99
-13.99	2021	0.99
-14.86	2386	0.99
-13.32	2347	0.99
-15.46	2096	0.99
-12.25	1637	0.99
-13.7	1797	0.99
0		
-12.37	2454	0.99
-15.03	2073	0.99
		. = .
-0.31	1.08	0.78
-12 29	1802	0.99
12.2)	1002	0.77
-0.82	1.08	0.44
	-13.95 -16.64 0.14 -0.7 -14.13 -13.99 -14.86 -13.32 -15.46 -12.25 -13.7 0 -12.37 -15.03 -0.31	-13.95 1622 -16.64 1879 0.14 0.71 -0.7 1.02 -14.13 2151 -13.99 2021 -14.86 2386 -13.32 2347 -15.46 2096 -12.25 1637 -13.7 1797 012.37 2454 -15.03 2073 -0.31 1.08

Discussion

This is the first report to demonstrate that anti-thrombotic drugs did not worsen the prognosis in patients with acute aortic dissection, in whom higher prevalence of previous history of atrial fibrillation and cardiovascular diseases were observed. Although there might be some hidden better conditions, the use of anti-thrombotic drugs during hospitalization showed significantly better prognosis in type A, which was observed even after adjustment for age and sex. Probably because more attention is paid in surgical repair in patients with anti-thrombotic drugs, anti-thrombotic drugs did not worsen the prognosis in acute aortic dissection. It is unknown if anti-thrombotic drugs have pharmacologically beneficial effects in the clinical course of acute aortic dissection.

Thrombus in False Lumen in Acute Aortic Dissection

After aortic dissection development, thrombus is often created in false lumen. It has been reported that the false lumen status is associated with poor outcomes[12]. The meta-analysis indicated that partial thrombosis in false lumen is independently associated with poor long-term survival in acute aortic dissection, compared with complete thrombosis or patent false lumen[12]. Although the underlying mechanisms involved in the

association between false lumen status and outcomes are not fully elucidated, complete thrombus formation of the false lumen has been considered to be a prerequisite for healing the aorta[12]. Also, complete thrombus may be able to relieve pressure from the tear; however, it may cause organ ischemia. In partial thrombosis in false lumen, organ ischemia may occur, and further, thrombus and platelets can modulate inflammatory reactions and immune responses. [13] [14] Although it remains unknown how anti-thrombotic drugs work on the thrombus formation in false lumen, the present study indicated that anti-thrombotic drugs did not worsen the prognosis in patients with acute aortic dissection. The mechanisms how anti-thrombotic drugs work in acute aortic dissection should be clarified in near future.

Initial Medical Therapy in Acute Aortic Dissection

Initial medical therapy should stabilize patients, control pain, and lower blood pressure to prevent further propagation of the dissection and to lessen the risk of aortic rupture.[9] The present study demonstrated that anti-thrombotic drugs do not worsen the prognosis; however, it is not recommended to newly introduce anti-thrombotic drugs before transfer of patients to comprehensive aortic centers or appropriate surgical consultation.[9]

Medical Management during Hospitalization

Blood pressure management is the most important.[9] β-Adrenergic blockade reduces not only heart rate and blood pressure, but also provides anti-impulse therapy to decrease aortic wall stress.[15] Besides appropriate blood pressure management, other therapeutic medical strategies are required. Although the present study demonstrated that the prognosis was comparable between with and without anti-thrombotic drugs during hospitalization in type B aortic dissection, anti-thrombotic drug group showed significantly better prognosis in patients with type A aortic dissection, suggesting that anti-thrombotic drugs might be a new therapeutic strategy in type A. On the other hand, anti-thrombotic drugs might not have been administered in poor condition, even if they were indicated. In the present study, we were not able to exclude confounding by indication.

Long-term Medical Management

Survival rate has been reported between 52% and 94% at 1 year and between 45% and 88% at 5 years in type A,[16] and between 56% and 92 % at 1 year and between 48% and 82% at 5 years in type B.[17] Long-term management of acute aortic dissection should be performed to prevent late phase complications, including aneurysmal enlargement and

aortic rupture. Poorly controlled hypertension has been reported to increase late morbidity and mortality.[18, 19] Thus, it is required to perform blood pressure control, screening the patient and relatives for heritable disorders associated with aortic dissection, serial imaging of the aorta, lifestyle modifications, and education.[16, 20] It should be clarified if anti-thrombotic drugs improve in these patients in near future.

Limitations

The present study has several limitations. First, the present study was an observational retrospective cohort study from a single center. Anti-thrombotic drugs were not administered for aortic dissection, but for other cardiovascular diseases, such as coronary artery diseases or atrial fibrillation. Second, the enrolled patients in the present study were hospitalized in University Hospital. These patients might be in more severe condition. Third, this study was not able to include the hidden severity data of acute aortic dissection except the obtained medical records in the present study, which may affect the prognosis. Fourth, confounding by indication cannot be excluded in anti-thrombotic drugs use in hospitalized patients with type A aortic dissection. Fifth, we have no available data of long-term prognosis.

354	Conclusion
355	We demonstrated that anti-thrombotic drugs did not worsen the prognosis in patients with
356	acute aortic dissection, indicating that we should not hesitate anti-thrombotic drugs if
357	indicated.
358	
359	Acknowledgements
360	None
361	
362	Sources of Funding
363	None.
364	
365	Disclosures
366	The authors declare no conflict of interest.
367	
368	

References 369 370 Goebel N, Nagib R, Salehi-Gilani S, Ahad S, Albert M, Ursulescu A, et al. One-371 1. 372 stage hybrid aortic repair using the frozen elephant trunk in acute DeBakey type I aortic 373 dissection. J Thorac Dis. 2018;10:4195-203. 374 2. Shimamoto T, Komiya T, Tsuneyoshi H. Fate of uncomplicated acute type B 375 aortic dissection and impact of concurrent aortic dilatation on remote aortic events. J 376 Thorac Cardiovasc Surg. 2019;157:854-863. 377 3. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part I: from etiology to diagnostic strategies. Circulation. 2003;108:628-378 379 35. 380 4. Hirst AE, Jr., Johns VJ, Jr., Kime SW, Jr. Dissecting aneurysm of the aorta: a review of 505 cases. Medicine (Baltimore). 1958;37:217-279. 381 382 5. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. J Intensive Care. 2018;6:15. 383 384 6. Kimura T, Shiraishi K, Furusho A, Ito S, Hirakata S, Nishida N, et al. Tenascin

Tahara N, Hirakata S, Okabe K, Tahara A, Honda A, Igata S, et al. FDG-PET/CT

C protects a rta from acute dissection in mice. Sci Rep. 2014;4:4051.

385

- images during 5 years before acute aortic dissection. Eur Heart J. 2016;37:1933.
- 388 8. Ohno-Urabe S, Aoki H, Nishihara M, Furusho A, Hirakata S, Nishida N, et al.
- Role of Macrophage Socs3 in the Pathogenesis of Aortic Dissection. J Am Heart Assoc.
- 390 2018;7:e007389.
- 391 9. Malaisrie SC, Szeto WY, Halas M, Girardi LN, Coselli JS, Sundt TM, 3rd, et al.
- 392 2021 The American Association for Thoracic Surgery expert consensus document:
- 393 Surgical treatment of acute type A aortic dissection. J Thorac Cardiovasc Surg.
- 394 2021;162:735-758 e2.
- 395 10. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S,
- 396 Standardization Committee of the International Society on T, Haemostasis. Definition of
- major bleeding in clinical investigations of antihemostatic medicinal products in non-
- surgical patients. J Thromb Haemost. 2005;3:692-694.
- 399 11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised
- 400 equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis.
- 401 2009;53:982-992.
- Li D, Ye L, He Y, Cao X, Liu J, Zhong W, et al. False Lumen Status in Patients
- 403 With Acute Aortic Dissection: A Systematic Review and Meta-Analysis. J Am Heart
- 404 Assoc. 2016;5:e003172.

- 405 13. Aoki H, Majima R, Hashimoto Y, Hirakata S, Ohno-Urabe S. Ying and Yang of
- Stat3 in pathogenesis of a ortic dissection. J Cardiol. 2021;77:471-474.
- Hamad MA, Krauel K, Schanze N, Gauchel N, Stachon P, Nuehrenberg T, et al.
- 408 Platelet Subtypes in Inflammatory Settings. Front Cardiovasc Med. 2022;9:823549.
- 409 15. Svensson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery:
- clinical observations, experimental investigations, and statistical analyses. Part I. Curr
- 411 Probl Surg. 1992;29:817-911.
- 412 16. Braverman AC. Acute aortic dissection: clinician update. Circulation.
- 413 2010;122:184-188.
- Tsai TT, Fattori R, Trimarchi S, Isselbacher E, Myrmel T, Evangelista A, et al.
- Long-term survival in patients presenting with type B acute aortic dissection: insights
- from the International Registry of Acute Aortic Dissection. Circulation. 2006;114:2226-
- 417 2231.
- 418 18. Melby SJ, Zierer A, Damiano RJ, Jr., Moon MR. Importance of blood pressure
- control after repair of acute type a aortic dissection: 25-year follow-up in 252 patients. J
- 420 Clin Hypertens (Greenwich). 2013;15:63-68.
- 421 19. Chan KK, Lai P, Wright JM. First-line beta-blockers versus other
- antihypertensive medications for chronic type B aortic dissection. Cochrane Database

Syst Rev. 2014;:CD010426.
20. Chaddha A, Eagle KA, Braverman AC, Kline-Rogers E, Hirsch AT, Brook R, et
al. Exercise and Physical Activity for the Post-Aortic Dissection Patient: The Clinician's
Conundrum. Clin Cardiol. 2015;38:647-651.
427
428
429

Figure legends 430 431 Figure 1. Enrollment of transferred patients with acute aortic dissection 432 433 Among 685 transferred patients, 15% in 454 type A and 16% in 231 type B patients had 434 already taken anti-thrombotic drugs. 435 Figure 2. Kapan-Meier curves of transferred patients with acute aortic dissection 436 437 There were no significant differences in survival rate between with and without anti-438 thrombotic drugs on admission in both type A (panel A) and B (panel B). 439 Figure 3. Enrollment of hospitalized patients with acute aortic dissection 440 441 Among 650 hospitalized patients, 43% in 424 type A and 19% in 225 type B patients 442 were treated by anti-thrombotic drugs during hospitalization. 443 444 Figure 4. Kapan-Meier curves of hospitalized patients with acute aortic dissection 445 Survival rate was significantly better in anti-thrombotic drug group than the other in type 446 A (panel A), while there was no significant difference between with and without antithrombotic drugs during hospitalization in type B (panel B). 447

Figure 1






Figure 2








Figure 4

